Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference

Core Insights - Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer and other conditions [3] - The company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025 [1] Company Overview - Olema Oncology is dedicated to transforming the standard of care for patients with breast cancer, advancing a pipeline of novel therapies [3] - The lead product candidate, palazestrant (OP-1250), is an orally available complete estrogen receptor antagonist and selective estrogen receptor degrader, currently in two Phase 3 clinical trials [3] - Olema is also developing OP-3136, a potent lysine acetyltransferase 6 inhibitor, which is in a Phase 1 clinical study [3] - The company is headquartered in San Francisco with operations in Cambridge, Massachusetts [3]